BioAxone BioSciences

Name

BioAxone BioSciences

Legal name

BioAxone BioSciences Inc.

Website

https://bioaxonebio.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceutical — CNS Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neural & Spinal Cord Regeneration (HLAAAGAI)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Clinical-stage biopharmaceutical
• Spinal cord injury therapy
• Neurovascular disorder treatments
• Rho signaling therapeutics
• Regenerative neuroscience drugs

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Licensing and Royalties: Pre-revenue clinical-stage company. Revenue model based on licensing drug candidates to pharmaceutical partners for clinical development and commercialization, with potential milestone payments and royalties on net sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BioAxone is a clinical-stage biopharmaceutical company developing drug candidates that target the Rho signaling pathway to treat spinal cord injury and cerebral cavernous malformation (CCM). Its lead asset, BA-210, is a locally delivered C3 transferase Rho inhibitor in Phase 3 for acute spinal cord injury; NRL-1049 is an oral ROCK2-selective inhibitor out-licensed to Neurelis for CCM; and BA-434 is a self-delivering RNAi compound targeting PTEN to promote axon regeneration.

Product overview

BioAxone BioSciences is a clinical-stage biopharmaceutical company that has developed three distinct drug candidates targeting neurological conditions. The company's portfolio includes BA-210 (VX-210), a locally-delivered Rho inhibitor for acute spinal cord injury currently in Phase 3; NRL-1049 (BA-1049), an orally-available ROCK2 inhibitor licensed to Neurelis for cerebral cavernous malformation in Phase 1; and BA-434, a self-delivering RNAi targeting PTEN for spinal cord injury. These therapies are based on deep expertise in Rho signaling pathways and axon regeneration mechanisms.

Differentiator

Problem solved

Functional benefit

Brands

• BA-210: Rho inhibitor drug candidate for acute spinal cord injury in Phase 3 clinical trials
• NRL-1049 (formerly BA-1049)
• BA-434

Products and services

• BA-210 (VX-210) A locally delivered protein drug (Rho inhibitor / C3 fusion protein) applied to the spinal cord injury site during surgical decompression. It is neuroprotective, triggers regeneration of injured axons, and promotes functional recovery. Currently in Phase 3 clinical trials for acute spinal cord injury; previously tested by Vertex Pharmaceuticals under license in the Phase 2b/3 SPRING Trial.
• NRL-1049 (formerly BA-1049) An orally available ROCK2-selective inhibitor out-licensed to Neurelis for the treatment of cerebral cavernous malformation (CCM/angioma) and other diseases of blood-brain barrier dysfunction. Neurelis filed an IND for NRL-1049 in January 2023; currently in Phase 1 clinical trials.
• BA-434 A self-delivering RNA interference (rxRNA) compound that targets transient, non-permanent suppression of PTEN (a protein that blocks axon regeneration in adult neurons) to promote long-distance regrowth of injured axons and reduce paralysis. Demonstrated efficacy in preclinical models of optic nerve injury and being developed for spinal cord injury.

Quantifiable outcome

• Signals of efficacy observed in 3mg dose group in Phase 2b/3 trial
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• NeureliscoreStrategic or Co-development Partner · 21 June 2021BioAxone signed a license agreement with Neurelis, a San Diego-based commercial-stage neuroscience company focused on development and commercialization of therapeutics for epilepsy and orphan diseases. Neurelis acquired rights to BA-1049 (now NRL-1049), a ROCK2-selective inhibitor for treatment of cerebral cavernous malformation (CCM). BioAxone received an upfront payment and is eligible for development and commercialization milestones plus royalties. Neurelis successfully filed an IND for NRL-1049 in January 2023.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Emerging players

• Kringle Pharma: Japanese clinical-stage biotech developing recombinant human HGF (hepatocyte growth factor) for spinal cord injury. Kringle is a regional player in the same SCI regenerative medicine space, with Phase 2/3 clinical data in Japan.
• Epirium Bio: Clinical-stage rare disease company developing therapies for muscular dystrophy and orphan neurological indications. Epirium shares BioAxone's small-team, licensing-oriented model in CNS/rare disease drug development.
• Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for neurological conditions including stroke and traumatic brain injury. Shares BioAxone's regenerative medicine focus on CNS disorders with a different therapeutic modality.
• Stemedica Cell Technologies: Clinical-stage company developing stem cell therapies for spinal cord injury and ischemic stroke. Comparable to BioAxone as an early-stage CNS regenerative medicine player targeting SCI with a different modality.

Others

• Vertex Pharmaceuticals: Previously BioAxone's licensee for BA-210 (run as VX-210) and sponsor of the SPRING Phase 2b/3 trial. Vertex halted the program after strategic refocus, making it a former partner rather than direct competitor, but illustrates how a top-tier pharma views SCI risk.
• Neurelis: Current licensee of NRL-1049 for cerebral cavernous malformation. San Diego-based commercial-stage neuroscience company focused on epilepsy and orphan diseases. Neurelis is BioAxone's partner, not a competitor, but shapes the CCM commercial trajectory.

Direct peers

• InVivo Therapeutics: Clinical-stage company historically focused on acute spinal cord injury treatment with cell-scaffold and polymer-based approaches. InVivo represents a direct peer in SCI drug development with comparable regulatory milestones and partner-seeking dynamics.
• NervGen Pharma: Clinical-stage biotech developing NVG-291, a peptide targeting PTPσ for spinal cord injury repair. NervGen is the closest direct competitor in CNS regeneration, sharing BioAxone's focus on overcoming inhibitory signaling to enable axon regeneration after SCI.
• Lineage Cell Therapeutics: Develops OPC1 (oligodendrocyte progenitor cell therapy) for spinal cord injury. Lineage is a direct peer in regenerative medicine for SCI, pursuing a different modality (cell therapy vs. BioAxone's Rho/ROCK inhibition) for the same indication.

Broad incumbents

• Acorda Therapeutics: Specialty neuroscience company with historic presence in spinal cord injury treatment (development of clinical-stage therapies and patient rehabilitation products). Acorda serves as a broad incumbent in the SCI/CNS space, having navigated the same regulatory and clinical development landscape.

Market position

Strengths5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bioaxone
• Facebookfacebook.com/bioaxone

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAxone BioSciences